Update on Inventiva's Share Capital and Voting Rights as of May 2026

Inventiva, a biopharmaceutical company, has issued a statement regarding its total voting rights and share capital as of May 22, 2026. As per the update, the company has 209,007,475 shares outstanding. These shares translate into 218,082,368 gross and net voting rights. The gross figure accounts for all shares with attached voting rights, while the net count excludes shares with suspended rights, such as treasury shares.

This information follows Article R. 22-10-23 of the French Commercial Code, ensuring transparent communication to the public. Inventiva's shares are listed on Euronext Paris under the code FR0013233012 and on the Nasdaq Global Market in the U.S. The company continues its clinical evaluation of lanifibranor for treating MASH, a progressive liver disease.